Online appointment booking firm DocPlanner has continued a healthy run of fundraisings with a €80 million Series E that takes the total it has raised above €130 million.
The first full regulatory approval for an amyloid-targeting therapy for Alzheimer’s disease could come within a month, after an expert panel voted 6 to 0 in favour of Eisa
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho